The Street Investor Awareness Says Advancements in the Biotech Market Makes for Impressive Gains Over The Next YearPR Web
Santa Ana California (PRWEB) August 10, 2012
While some biotech companies start out unprofitable, savvy penny stock investors that see potential in biotech firms continue to see high-gains in a short period of time as some stocks have seen jumps as high as 157% . Many of these shares soar as the companies release positive clinical study data or work towards phase 1 drug approval through the FDA.
Pluristem Therapeutics, Inc. is up 157% in the last 12 months and 108% year-to-date. Pluristem Therapeutics, Inc has tripled its 52-week low of 98 cents and was at a midday high of $3.37 on 8/2/2012. is a leading developer of placenta-based cell therapies and recently released the results of new preclinical tests that show its Placental expanded cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease.
CEO of TheStreetInvestorAwareness.com, James Edington, offered up his opinion on why the biotech market can be prove to be so successful for savvy investors who understand how FDA approval works, and why announcements of positive clinical trial data from biotech firms such as OncoSec Medical Inc. is important.
OncoSec Medical Inc. is not yet a major player, but is quickly gaining ground and is a hot stock to watch. While they are still in development phases, they have seen positive gains in the area of clinical studies, and their data is promising. They are continuing to work towards developing therapies that are measurable. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. certain assets related to the use of drug-medical device combination products for the treatment of different cancers. In July 2012, Onco Sec Medical Inc. reported that a clinical trial to treat head and neck tumors showed an improved quality of life for patients compared to surgery. At last check, OncoSec Medical Inc. shares were trading 14.89% lower at $0.200 on above average volume of 4.42 million, but are expected to rally as more promising news is announced.
To receive frequent stock report alerts and become a member of TheStreetInvestorAwareness, visit http://www.TheStreetInvestorAwareness.com.
Read the full story at http://www.prweb.com/releases/2012/8/prweb9784213.htm